Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.

Viral load (VL) measurements are critical to the proper management of HIV in developing countries. However, access to VL assays is limited by the high cost and complexity of existing assays. While there is a need for low cost VL assays, performance must not be compromised. Thus, new assays must be v...

Full description

Bibliographic Details
Main Authors: Scott M Berry, Hannah M Pezzi, Eram D Williams, Jennifer M Loeb, David J Guckenberger, Alex J Lavanway, Alice A Puchalski, Cissy M Kityo, Peter N Mugyenyi, Franklin M Graziano, David J Beebe
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4667969?pdf=render
id doaj-e27f0af4b9674333b40c80b2912e51a7
record_format Article
spelling doaj-e27f0af4b9674333b40c80b2912e51a72020-11-25T02:31:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014363110.1371/journal.pone.0143631Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.Scott M BerryHannah M PezziEram D WilliamsJennifer M LoebDavid J GuckenbergerAlex J LavanwayAlice A PuchalskiCissy M KityoPeter N MugyenyiFranklin M GrazianoDavid J BeebeViral load (VL) measurements are critical to the proper management of HIV in developing countries. However, access to VL assays is limited by the high cost and complexity of existing assays. While there is a need for low cost VL assays, performance must not be compromised. Thus, new assays must be validated on metrics of limit of detection (LOD), accuracy, and dynamic range. Patient plasma samples from the Joint Clinical Research Centre in Uganda were de-identified and measured using both an existing VL assay (Abbott RealTime HIV-1) and our assay, which combines low cost reagents with a simplified method of RNA isolation termed Exclusion-Based Sample Preparation (ESP).71 patient samples with VLs ranging from <40 to >3,000,000 copies/mL were used to compare the two methods. We demonstrated equivalent LOD (~50 copies/mL) and high accuracy (average difference between methods of 0.08 log, R2 = 0.97). Using expenditures from this trial, we estimate that the cost of the reagents and consumables for this assay to be approximately $5 USD. As cost is a significant barrier to implementation of VL testing, we anticipate that our assay will enhance access to this critical monitoring test in developing countries.http://europepmc.org/articles/PMC4667969?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Scott M Berry
Hannah M Pezzi
Eram D Williams
Jennifer M Loeb
David J Guckenberger
Alex J Lavanway
Alice A Puchalski
Cissy M Kityo
Peter N Mugyenyi
Franklin M Graziano
David J Beebe
spellingShingle Scott M Berry
Hannah M Pezzi
Eram D Williams
Jennifer M Loeb
David J Guckenberger
Alex J Lavanway
Alice A Puchalski
Cissy M Kityo
Peter N Mugyenyi
Franklin M Graziano
David J Beebe
Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.
PLoS ONE
author_facet Scott M Berry
Hannah M Pezzi
Eram D Williams
Jennifer M Loeb
David J Guckenberger
Alex J Lavanway
Alice A Puchalski
Cissy M Kityo
Peter N Mugyenyi
Franklin M Graziano
David J Beebe
author_sort Scott M Berry
title Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.
title_short Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.
title_full Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.
title_fullStr Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.
title_full_unstemmed Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.
title_sort using exclusion-based sample preparation (esp) to reduce viral load assay cost.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Viral load (VL) measurements are critical to the proper management of HIV in developing countries. However, access to VL assays is limited by the high cost and complexity of existing assays. While there is a need for low cost VL assays, performance must not be compromised. Thus, new assays must be validated on metrics of limit of detection (LOD), accuracy, and dynamic range. Patient plasma samples from the Joint Clinical Research Centre in Uganda were de-identified and measured using both an existing VL assay (Abbott RealTime HIV-1) and our assay, which combines low cost reagents with a simplified method of RNA isolation termed Exclusion-Based Sample Preparation (ESP).71 patient samples with VLs ranging from <40 to >3,000,000 copies/mL were used to compare the two methods. We demonstrated equivalent LOD (~50 copies/mL) and high accuracy (average difference between methods of 0.08 log, R2 = 0.97). Using expenditures from this trial, we estimate that the cost of the reagents and consumables for this assay to be approximately $5 USD. As cost is a significant barrier to implementation of VL testing, we anticipate that our assay will enhance access to this critical monitoring test in developing countries.
url http://europepmc.org/articles/PMC4667969?pdf=render
work_keys_str_mv AT scottmberry usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT hannahmpezzi usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT eramdwilliams usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT jennifermloeb usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT davidjguckenberger usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT alexjlavanway usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT aliceapuchalski usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT cissymkityo usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT peternmugyenyi usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT franklinmgraziano usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
AT davidjbeebe usingexclusionbasedsamplepreparationesptoreduceviralloadassaycost
_version_ 1724824881168646144